SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novavax, Inc. - NVAX

NEW YORK, Dec. 19, 2017 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Novavax, Inc. ("Novavax" or the "Company") (NASDAQ: NVAX).   Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980.

The investigation concerns whether Novavax and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here to join a class action]

In November 2017, Novavax projected a year-end release for top-line data from the Company's Phase 1/2 clinical trial of its NanoFlu Vaccine.  Then, on December 19, 2017, Novavax announced that a "complete package" will not be completed and released until February 2018.  Novavax advised investors that "the wild-type viruses necessary to assess immunogenicity of the vaccines to circulating strains have been difficult to obtain, grow and maintain genetic stability." 

On this news, Novavax's share price has fallen sharply during intraday trading on December 19, 2017.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

CONTACT:
Robert S. Willoughby
Pomerantz LLP
rswilloughby@pomlaw.com

View original content:http://www.prnewswire.com/news-releases/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-novavax-inc--nvax-300573420.html

SOURCE Pomerantz LLP